SecBot SecBot
SECBOTREPLAY Home › Report › KMDA

KMDA · Kamada announced a three-year agreement to supply normal source plasma…

KAMADA LTD · 6-K filed Jul 20, 2026 at 07:00 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jul 20, 2026 at 07:00 ET

Kamada announced a three-year agreement to supply normal source plasma from its Texas collection centers to a leading biopharmaceutical company, expected to generate approximately $50 million in revenue over three years. Initial commercial sales are expected in Q4 2026, and this agreement validates the company's investment in its U.S. plasma collection operations, supporting its vertical-integration strategy and multi-year revenue growth objectives. The agreement is included in the company's current annual guidance, which projects total revenues of $200-$205 million and adjusted EBITDA of $50-$53 million for fiscal year 2026.

  • Kamada entered a three-year agreement to supply normal source plasma to a leading biopharmaceutical company.
  • The agreement is expected to generate approximately $50 million in revenue over three years.
  • Initial commercial sales are expected to be recorded in Q4 2026.
  • Plasma will be sourced from Kamada's FDA-approved collection centers in Houston and San Antonio, Texas.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access